1. Introduction {#sec1}
===============

PPARs are members of the nuclear receptor superfamily \[[@B1]\]. Three isotypes designated PPAR*α*, PPAR*β*/*δ*, and PPAR*γ* have been described in mammals \[[@B2]\]. The PPARs form heterodimers with the retinoid X receptor (RXR), and the PPAR-RXR heterodimers, when bound to a ligand, change their conformation and bind to the DNA at the PPAR response elements, which results in gene transcription \[[@B3], [@B4]\]. PPAR*γ* is expressed in adipose tissue, heart, kidney, skeletal muscle, liver and other organs PPAR*γ* ligands improve insulin resistance and inflammation by increasing serum adiponectin levels \[[@B5]--[@B7]\]. Thus, thiazolidinediones (TZDs), which are PPAR*γ* ligands, are widely used in the treatment of type 2 diabetes mellitus (DM).

Liver injury is caused by various factors such as viral infections, autoimmune reactions, and metabolic disorders. Recently, PPAR*γ* agonists have received attention in relation to the treatment of liver diseases. PPAR*γ* has been reported to reduce hepatic inflammation by decreasing the expression of tumor necrosis factor*α* (TNF-*α*) \[[@B8]\], and suppressing the translocation of NF-*κ*B into the nucleus \[[@B9]\]. Furthermore, the PPAR pathway inhibits the fibrogenic actions in hepatic stellate cells and attenuates liver fibrosis *in vivo* \[[@B10], [@B11]\]. PPAR*γ* agonists have been reported to be useful in mice and humans with NAFLD \[[@B12]--[@B14]\], as PPAR*γ* promotes adipocyte differentiation \[[@B15]\], increases triglyceride storage in adipocyte, and reduces delivery of fatty acids to the liver \[[@B9]\]. However the effect on other liver diseases has not yet been investigated.

In this study, PPAR*γ* ligands and PPAR*γ* ^+/−^ mice were used to confirm the effects of PPAR*γ* on the liver injury induced by Con A. Con A induces serious hepatitis in mice by activating T cells and triggering apoptosis \[[@B16], [@B17]\].

2. Materials and Methods {#sec2}
========================

2.1. Animal Experiments {#sec2.1}
-----------------------

Eight-week-old male WT BALB/c mice and eight-week-old male PPAR*γ* ^+/−^ mice on a BALB/c background were purchased from CLEA Japan, Inc. and Jackson Laboratory (Bar Harbor, ME, USA), respectively. All the mice were maintained in filter-topped cages on autoclaved normal chow diet containing 22% protein, 6% fat, and 47% carbohydrate. In the Con A-induced hepatitis model, Con A (Sigma Aldrich, St. Louis, MO, USA; 20 mg/kg) was injected intravenously (i.v.) into mice. First, WT mice (*n* = 6 mice) were fed either a control chow or chow supplemented with one of the two types of PPAR*γ* ligands (ciglitazone (100 mg/kg) and troglitazone (150 mg/kg)) *ad libitum* for 1 week and sacrificed at 20 h after the Con A injection. These doses and duration of treatment with the PPAR*γ* agonists were selected based on the efficacy demonstrated in pilot experiments (data not shown). Subsequently, PPAR*γ* ^+/−^ mice were treated with either control chow or pioglitazone-supplemented chow and sacrificed at 20 h after the Con A injection. Finally, to investigate the effect of PPAR*γ* on the activation of NF-*κ*B induced by Con A, control or pioglitazone-supplemented chow was administered to the WT mice and sacrificed at various time points (0.5 h, 1 h, 3 h, 6 h, and 8 h) after the Con A injection, to obtain nuclear protein. The animal protocols were approved by the Yokohama City University Medical School Guidelines for the Care and Use of Laboratory Animals.

2.2. Biochemistry {#sec2.2}
-----------------

Serum alanine aminotransferase (ALT) levels were measured by a local laboratory for clinical examinations (SRL Co, Ltd., Tokyo, Japan).

2.3. Liver Histology {#sec2.3}
--------------------

Liver specimens were fixed overnight in buffered formaldehyde (10%) and embedded in paraffin. Paraffin sections were prepared at 5 *μ*m thickness and stained with hematoxylin and eosin (H-E).

2.4. Assay for Apoptosis {#sec2.4}
------------------------

The apoptotic tumor cells were stained using a TUNEL staining kit, according to the manufacturer\'s instructions (Wako Pure Chemical, Osaka, Japan). In brief, paraffin sections were digested with 20 *μ*g/mL of proteinase K (Takara, Shiga, Japan) for 15 min at room temperature and reacted with terminal deoxynucleotidyl transferase enzyme for 60 min at 37°C. The sections were then incubated with antidigoxigenin conjugate at room temperature for 30 min, followed by incubation with diaminobenzidine solution.

2.5. Electrophoretic Mobility Shift Assay (EMSA) {#sec2.5}
------------------------------------------------

NF-*κ*B binding was determined by EMSA. We collected liver tissue specimens at various time points (0.5, 1, 3, 6, and 8 h) after the Con A injection. Nuclear protein extracts (10 *μ*g) were prepared using Nuclear Extraction kit (BizScience, Osaka, Japan), according to the manufacturer\'s instructions. The probe oligonucleotide was 22 bp, double-stranded (5′-GCCTGGGAAAGTCCCCTCAACT-3′) and endlabeled with biotin (Sigma Chemical, St. Louis, MO). DNA-protein complexes were resolved at 80 V for 1 h in a taurine-buffered, native 6% polyacrylamide gel (4% for supershift) and blotted onto a positively charged nylon membrane (Sigma Chemical, St. Louis, MO). Transferred DNA was immediately cross-linked to the membrane on an ultraviolet transilluminator equipped with 312 nm bulbs and detected using horseradish peroxidase-conjugated streptavidin (Light-Shift Chemiluminescent EMSA kit), according to the manufacturer\'s instructions.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Data are presented as means ± SD. Differences between the two groups were assessed using the unpaired two-tailed Student\'s *t*-test; *P* values of \<0.05 were considered to denote significance. All statistical analyses were performed using Microsoft Excel and the SPSS 16.0 statistical package (SPSS, Chicago, IL).

3. Results and Discussion {#sec3}
=========================

To assess the degree of liver injury, we analyzed the time course of changes of the serum ALT levels after the Con A injection. Unexpectedly, the serum ALT levels in the pioglitazone- (30 mg/kg) treated mice were significantly higher in comparison with that in the nonpioglitazone-treated mice at 20 h after Con A injection ([Figure 1(a)](#fig1){ref-type="fig"}). The survival rate of the nonpioglitazone-treated mice was 100%, while that of the pioglitazone- (30 mg/kg) treated mice was 30% at 20 h after Con A injection ([Figure 2](#fig2){ref-type="fig"}). Subsequently, we conducted a histological examination to assess the degree of Con A-induced liver injury at 20 h after Con A injection in the mice treated and not treated with 30 mg/kg of pioglitazone. Histopathological examination of tissue sections stained with H-E revealed that the liver damage was more extensive in the pioglitazone-treated mice as compared with that in the nonpioglitazone-treated mice (Figures [3(a)](#fig3){ref-type="fig"} and [3(c)](#fig3){ref-type="fig"}). To determine the presence and extent of apoptotic cells, we performed TUNEL assay. More TUNEL-positive hepatocytes could be detected in the liver sections of the pioglitazone-treated mice than in those of the control mice (Figures [3(b)](#fig3){ref-type="fig"} and [3(d)](#fig3){ref-type="fig"}). The number of TUNEL positive cells/100 cells in the livers of the pioglitazone-treated mice was three-times higher as compared with that in the livers of the nonpioglitazone-treated mice (56.2 ± 8.0 versus 21.0 ± 1.8, *P* \< 0.001). From these results, we hypothesized that PPAR*γ* might actually exacerbate Con A-induced liver injury by intensifying hepatocyte apoptosis. Then, we used two other PPAR*γ* ligands (ciglitazone and troglitazone) to confirm the effect of PPAR*γ*. All of the three PPAR*γ* ligands produced a significant increase of the serum ALT levels in the treated mice as compared with the levels in the untreated mice (Figures [1(a)](#fig1){ref-type="fig"}, [1(b)](#fig1){ref-type="fig"}, and [1(c)](#fig1){ref-type="fig"}). This result indicates that PPAR*γ* ligands exacerbate Con A-induced liver injury regardless of the kinds.

To evaluate the effect of PPAR*γ* on liver injury, we used PPAR*γ* ^+/−^ mice. The reason for using the heterologous PPAR*γ* ^+/−^ mice was that double knock-out of this gene results in embryonic lethality. Con A-induced liver injury was less extensive in the PPAR*γ* ^+/−^ mice as compared with that in the WT mice ([Figure 4](#fig4){ref-type="fig"}). This result suggests the possible involvement of the endogenous PPAR*γ*-mediated pathway in the exacerbation of Con A-induced liver injury.

To confirm the apoptosis in the pioglitazone-treated and nonpioglitazone-treated mice after Con A-injection, we analyzed the expression of NF-*κ*B, which is a known suppressor of apoptosis. To determine the quantity of activated NF-*κ*B, we performed EMSA. Activation of NF-*κ*B in the hepatocyte nuclei after Con A-injection was suppressed in the livers of the pioglitazone-treated mice as compared with that in the livers of the nonpioglitazone-treated mice ([Figure 5](#fig5){ref-type="fig"}). This result suggests that PPAR*γ* suppresses the translocation of NF-*κ*B into the nucleus, thereby inhibiting the suppression of liver cell apoptosis. Maeda et al. reported that hepatocyte-specific IKK*β* knockout mice exhibit little NF-*κ*B activity and are highly susceptible to liver apoptosis of Con A-induced liver injury \[[@B18]\].

From this study, suppression of PPAR*γ*, such as using PPAR*γ* antagonists may potentially reduce the extent of liver injury.

4. Conclusion {#sec4}
=============

In this study, we showed that PPAR*γ* ligands exacerbate Con A-induced liver injury via suppressing the translocation of NF-*κ*B into the nucleus. Con A-induced liver injury in PPAR*γ*-treated mice represents an intensified apoptosis. PPAR*γ* antagonists may be considered as novel candidates for the therapy of liver injury in an intensifying apoptosis model.
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![At 20 h after Con A injection, the serum ALT levels in the mice treated with one of the three types of PPAR*γ* ligands (pioglitazone (a), troglitazone (b), ciglitazone (c)) were significantly higher as compared with those in the non-PPAR*γ*-treated mice (\**P* \< 0.05).](PPAR2012-940384.001){#fig1}

![At 20 h after Con A injection, there were no cases of fatality in the nonpioglitazone-treated group of mice, whereas the fatality rate was 70% in the pioglitazone-treated mice.](PPAR2012-940384.002){#fig2}

![Histopathological examination of liver sections stained with H-E at 20 h after Con A injection revealed more extensive liver necrosis in the pioglitazone-treated mice (c) in comparison with that in the nonpioglitazone-treated mice (a). TUNEL assay at 20 h after Con A injection revealed more extensive liver apoptosis in the pioglitazone-treated mice (d) as compared with that in the nonpioglitazone-treated mice (b). The number of TUNEL-positive cells/100 cells was three-times higher in the livers of the pioglitazone-treated mice as compared with that in the livers of the nonpioglitazone-treated mice (56 ± 8.01 versus 21 ± 1.83, *P* \< 0.001).](PPAR2012-940384.003){#fig3}

![At 20 h after Con A injection, the serum ALT levels in the WT mice were significantly higher than those in the PPAR*γ* ^+/−^ mice.](PPAR2012-940384.004){#fig4}

![NF-*κ*B binding was determined by EMSA. We collected liver tissue specimens at various time points (0.5, 1, 3, 6, and 8 h) after Con A injection. At 1 h after the Con A injection, NF-*κ*B was activated in the nonpioglitazone-treated mice, whereas the NF-*κ*B activation was suppressed in the pioglitazone-treated mice.](PPAR2012-940384.005){#fig5}
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